Skip to main content
Top
Published in: Annals of Surgical Oncology 12/2021

01-11-2021 | Melanoma | ASO Perspectives

Prognosis in Thin Melanoma Patients: Is Slightly Less Than Excellent Still Okay?

Author: Michael E. Egger, MD, MPH

Published in: Annals of Surgical Oncology | Issue 12/2021

Login to get access

Excerpt

The postoperative visit for patients with melanoma is usually a simple affair. After a few postoperative visits with patients undergoing pancreatectomy, gastrectomy, or other gastrointestinal resections, it is nice to see melanoma patients looking and feeling well so quickly after surgery. The incision (usually) looks good, the pathology report shows no residual melanoma, and the question of ‘what next’ is a simple one to answer—no additional treatment, no laboratory tests or imaging studies, see your dermatologist regularly, and I will see you once a year. Of course, things get a little more nuanced for patients with high-risk stage II and III disease, but those conversations are a lot more hopeful than they were a decade ago. Nonetheless, in the back of my mind, there is that nagging little factoid that has been reported several times … yes, most patients with thin melanoma are cured, but most patients who die of melanoma are originally diagnosed with a thin melanoma.1,2 However, that patient in front of you, at that moment of anxiety and vulnerability, does not need to hear about these epidemiologic quirks in the data. They just need to know if they are going to be okay, and, for the vast majority of patients, the answer is ‘yes’. …
Literature
1.
go back to reference Landow SM, Gjelsvik A, Weinstock MA. Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992–2013. J Am Acad Dermatol. 2017;76(2):258–63.CrossRef Landow SM, Gjelsvik A, Weinstock MA. Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992–2013. J Am Acad Dermatol. 2017;76(2):258–63.CrossRef
2.
go back to reference Whiteman DC, Baade PD, Olsen CM. More people die from thin melanomas (≤1 mm) than from thick melanomas (>4 mm) in Queensland, Australia. J Investig Dermatol. 2015;135(4):1190–3.CrossRef Whiteman DC, Baade PD, Olsen CM. More people die from thin melanomas (≤1 mm) than from thick melanomas (>4 mm) in Queensland, Australia. J Investig Dermatol. 2015;135(4):1190–3.CrossRef
3.
go back to reference El Sharouni MA, Ahmed T, Varey AHR, et al. Development and validation of nomograms to predict local, regional, and distant recurrence in patients with thin (T1) melanomas. J Clin Oncol. 2021;39(11):1243–52.CrossRef El Sharouni MA, Ahmed T, Varey AHR, et al. Development and validation of nomograms to predict local, regional, and distant recurrence in patients with thin (T1) melanomas. J Clin Oncol. 2021;39(11):1243–52.CrossRef
4.
go back to reference Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Br J Surg. 2015;102(3):148–58.CrossRef Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Br J Surg. 2015;102(3):148–58.CrossRef
5.
go back to reference Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer Eighth Edition cancer staging manual. CA Cancer J Clin. 67(6): 472–492 Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer Eighth Edition cancer staging manual. CA Cancer J Clin. 67(6): 472–492
6.
go back to reference Lo SN, Ma J, Scolyer RA, et al. Improved risk prediction calculator for sentinel node positivity in patients with Melanoma: The Melanoma Institute Australia Nomogram. J Clin Oncol. 2020;38(24):2719–27.CrossRef Lo SN, Ma J, Scolyer RA, et al. Improved risk prediction calculator for sentinel node positivity in patients with Melanoma: The Melanoma Institute Australia Nomogram. J Clin Oncol. 2020;38(24):2719–27.CrossRef
7.
go back to reference Wong SL, Kattan MW, McMasters KM, Coit DG. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system. Ann Surg Oncol. 2005;12(4):282–8.CrossRef Wong SL, Kattan MW, McMasters KM, Coit DG. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system. Ann Surg Oncol. 2005;12(4):282–8.CrossRef
8.
go back to reference Meyers MO, Yeh JJ, Frank J, et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. Ann Surg Oncol. 2009;16(4):941–7.CrossRef Meyers MO, Yeh JJ, Frank J, et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. Ann Surg Oncol. 2009;16(4):941–7.CrossRef
9.
go back to reference Lee AY, Droppelmann N, Panageas KS, et al. Patterns and timing of initial relapse in pathologic stage II Melanoma patients. Ann Surg Oncol. 2017;24(4):939–46.CrossRef Lee AY, Droppelmann N, Panageas KS, et al. Patterns and timing of initial relapse in pathologic stage II Melanoma patients. Ann Surg Oncol. 2017;24(4):939–46.CrossRef
10.
go back to reference Smith-Bindman R, Lipson J, Marcus R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med. 2009;169(22):2078–86.CrossRef Smith-Bindman R, Lipson J, Marcus R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med. 2009;169(22):2078–86.CrossRef
11.
go back to reference Berrington de González A, Mahesh M, Kim KP, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med. 2009;169(22):2071–2077. Berrington de González A, Mahesh M, Kim KP, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med. 2009;169(22):2071–2077.
12.
go back to reference Gastman BR, Gerami P, Kurley SJ, Cook RW, Leachman S, Vetto JT. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. J Am Acad Dermatol. 2019;80(1):149-157.e144.CrossRef Gastman BR, Gerami P, Kurley SJ, Cook RW, Leachman S, Vetto JT. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. J Am Acad Dermatol. 2019;80(1):149-157.e144.CrossRef
13.
go back to reference Zager JS, Gastman BR, Leachman S, et al. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer. 2018;18(1):130.CrossRef Zager JS, Gastman BR, Leachman S, et al. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer. 2018;18(1):130.CrossRef
14.
go back to reference Vetto JT, Hsueh EC, Gastman BR, et al. Guidance of sentinel lymph node biopsy decisions in patients with T1–T2 melanoma using gene expression profiling. Future Oncol. 2019;15(11):1207–17.CrossRef Vetto JT, Hsueh EC, Gastman BR, et al. Guidance of sentinel lymph node biopsy decisions in patients with T1–T2 melanoma using gene expression profiling. Future Oncol. 2019;15(11):1207–17.CrossRef
15.
go back to reference Lo SN, Scolyer RA, Thompson JF. Long-term survival of patients with thin (T1) cutaneous Melanomas: a breslow thickness cut point of 0.8 mm separates higher-risk and lower-risk tumors. Ann Surg Oncol. 2018;25(4):894–902. Lo SN, Scolyer RA, Thompson JF. Long-term survival of patients with thin (T1) cutaneous Melanomas: a breslow thickness cut point of 0.8 mm separates higher-risk and lower-risk tumors. Ann Surg Oncol. 2018;25(4):894–902.
16.
go back to reference Isaksson K, Mikiver R, Eriksson H, et al. Survival in 31 670 patients with thin melanomas: a Swedish population-based study. Br J Dermatol. 2021;184(1):60–7.CrossRef Isaksson K, Mikiver R, Eriksson H, et al. Survival in 31 670 patients with thin melanomas: a Swedish population-based study. Br J Dermatol. 2021;184(1):60–7.CrossRef
17.
go back to reference Ferrone CR, Ben Porat L, Panageas KS, et al. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA. 2005;294(13):1647–54.CrossRef Ferrone CR, Ben Porat L, Panageas KS, et al. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA. 2005;294(13):1647–54.CrossRef
18.
go back to reference Helgadottir H, Isaksson K, Fritz I, et al. Multiple primary melanoma incidence trends over five decades: a nationwide population-based study. J Natl Cancer Inst. 2021;113(3):318–28.CrossRef Helgadottir H, Isaksson K, Fritz I, et al. Multiple primary melanoma incidence trends over five decades: a nationwide population-based study. J Natl Cancer Inst. 2021;113(3):318–28.CrossRef
19.
go back to reference Youlden DR, Youl PH, Soyer HP, Aitken JF, Baade PD. Distribution of subsequent primary invasive melanomas following a first primary invasive or in situ melanoma in Queensland, Australia, 1982–2010. JAMA Dermatol. 2014;150(5):526–34.CrossRef Youlden DR, Youl PH, Soyer HP, Aitken JF, Baade PD. Distribution of subsequent primary invasive melanomas following a first primary invasive or in situ melanoma in Queensland, Australia, 1982–2010. JAMA Dermatol. 2014;150(5):526–34.CrossRef
20.
go back to reference Cust AE, Badcock C, Smith J, et al. A risk prediction model for the development of subsequent primary melanoma in a population-based cohort. Br J Dermatol. 2020;182(5):1148–57.CrossRef Cust AE, Badcock C, Smith J, et al. A risk prediction model for the development of subsequent primary melanoma in a population-based cohort. Br J Dermatol. 2020;182(5):1148–57.CrossRef
Metadata
Title
Prognosis in Thin Melanoma Patients: Is Slightly Less Than Excellent Still Okay?
Author
Michael E. Egger, MD, MPH
Publication date
01-11-2021
Publisher
Springer International Publishing
Keywords
Melanoma
Melanoma
Published in
Annals of Surgical Oncology / Issue 12/2021
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-021-10772-x

Other articles of this Issue 12/2021

Annals of Surgical Oncology 12/2021 Go to the issue